Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment Global Market Report 2024

The urinary incontinence & pelvic organ prolapse devices and equipment market size has grown strongly in recent years. It will grow from $0.45 billion in 2023 to $0.48 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth observed in the historical period can be ascribed to several factors, including the aging population, increased awareness of women's health, improved healthcare access, and the adoption of personalized treatment approaches.

The urinary incontinence & pelvic organ prolapse devices and equipment market size is expected to see strong growth in the next few years. It will grow to $0.6 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth can be attributed to various factors, including the increasing use of minimally invasive techniques, expansion into emerging markets, the adoption of value-based healthcare models, and regulatory support. Moreover, several noteworthy trends are expected to shape the landscape during the forecast period. These trends encompass the rise of non-surgical treatment options, the utilization of bioresorbable implants, the integration of digital health solutions, and the enhancement of patient education efforts. These developments are likely to contribute significantly to the urinary incontinence and pelvic organ prolapse devices and equipment market.

The increased prevalence of Pelvic Organ Prolapse (POP) and Urinary Incontinence (UI) disorders has been a driving force behind the growth of the market for urinary incontinence and pelvic organ prolapse (POP) devices and equipment. This rising prevalence has prompted manufacturers to develop more precise and effective devices for treating these conditions. While POP can affect women of all ages, it is more common in older women. According to reports from the US FDA, the number of women with POP is projected to increase by 46%, reaching 4.9 million by 2050. Additionally, a report from the American Urological Association (AUA/SUFU) found that the prevalence of stress urinary incontinence (SUI) in women can be as high as 49%. Poor nutritional status can lead to a higher prevalence of SUI due to the weakening of pelvic support. This increased prevalence is fueling the demand for medical equipment in the urinary incontinence and pelvic organ prolapse devices and equipment market.

These devices can be categorized into two main types such as urinary incontinence devices and pelvic organ prolapse devices. Urinary incontinence devices encompass items like artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters, which are utilized to address urinary incontinence. In contrast, pelvic organ prolapse devices include vaginal mesh and vaginal pessaries, designed to manage pelvic organ prolapse. Urinary incontinence can manifest in various forms, including stress incontinence, urge incontinence, overflow incontinence, and functional incontinence. These devices find applications across different healthcare settings, such as hospitals, clinics, ambulatory surgical centers, and for at-home use.

The urinary incontinence & pelvic organ prolapse devices and equipment market research report is one of a series of new reports that provides urinary incontinence & pelvic organ prolapse devices and equipment market statistics, including urinary incontinence & pelvic organ prolapse devices and equipment industry global market size, regional shares, competitors with a urinary incontinence & pelvic organ prolapse devices and equipment market share, detailed urinary incontinence & pelvic organ prolapse devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the urinary incontinence & pelvic organ prolapse devices and equipment industry. This urinary incontinence & pelvic organ prolapse devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growing geriatric population is expected to be a significant driver of the urinary incontinence and pelvic organ prolapse devices and equipment market in the future. The geriatric population refers to individuals aged 65 and older and is susceptible to urinary incontinence and pelvic organ prolapse, necessitating the use of various devices and equipment for managing these conditions. According to the World Health Organization (WHO), by 2050, 80% of older people are projected to reside in low- and middle-income countries. Between 2015 and 2050, the proportion of the global population over 60 years old is expected to nearly double, from 12% to 22%. Hence, the expanding geriatric population is a driving factor for the urinary incontinence and pelvic organ prolapse devices and equipment market.

The urinary incontinence and pelvic organ prolapse devices and equipment market is facing limitations due to health issues associated with the use of vaginal mesh in the treatment of UI and POP. Regulatory authorities like the FDA and NICE have introduced new guidelines for manufacturers to address these concerns. Vaginal mesh implants typically incorporate a Polypropylene layer, which has led to severe medical complications in countless women worldwide. As a result, manufacturers are compelled to explore alternative materials, such as polyurethane, that are better suited for use by women without causing health complications in the treatment of pelvic organ prolapse and urinary incontinence. For instance, in October 2022, the Food and Drug Administration, a US-based regulator of drugs and medical devices, maintained its ban on transvaginal mesh after a 36-month study on its use for pelvic organ prolapse, citing a low risk-to-benefit ratio. These safety concerns surrounding vaginal mesh have resulted in more stringent manufacturing regulations and have had an impact on sales, thus impeding the urinary incontinence and pelvic organ prolapse devices and equipment market.

Prominent companies in the urinary incontinence and pelvic organ prolapse devices and equipment market are introducing innovative solutions like the SOLTIVE Super Pulsed Laser System to enhance their market revenue. The SOLTIVE Premium Super Pulsed Laser System, known as the SOLTIVE Laser System, has the potential to reduce procedure duration, improve patient outcomes, and lower the overall procedure costs. This system is applied in the treatment of urinary incontinence and various urological conditions, including the removal of kidney stones. For instance, in January 2022, Olympus, a Japanese company specializing in digital precision technology, introduced the SOLTIVE Super Pulsed Laser System, which offers significant advantages in terms of shorter procedure times and cost-effectiveness when compared to Holmium. The SOLTIVE Laser System, on average, reduces procedure times by 20% and holds the promise of achieving better patient outcomes.

Devices such as the Lyrette transurethral SUI system are employed in procedures to address incontinence. Lyrette treatment does not necessitate the use of anesthesia or surgery; instead, it utilizes radiofrequency energy to tighten the bladder tissue. In the case of treating pelvic organ prolapse (POP), companies are shifting their focus towards native tissue prolapse repair procedures rather than relying on vaginal mesh, following the emergence of health concerns associated with its use.

Regulatory bodies, including the FDA in the United States, play a pivotal role in overseeing the manufacturing and safety standards for devices and equipment related to urinary incontinence and pelvic organ prolapse disorders. For instance, manufacturers are mandated to obtain pre-market clearance (510(k)) for tools specifically designed for implanting surgical mesh. The FDA further requires manufacturers in the urinary incontinence and pelvic organ prolapse devices and equipment industry to conduct post-market studies to assess the safety and effectiveness of surgical mesh used in POP repair. As a result, FDA regulations have led to the removal of certain products from the market and compelled companies like Coloplast and Acell to discontinue marketing their respective products, namely Coloplast's Restorelle DirectFix Posterior and Acell Matristem's Pelvic Floor Repair Matrix.

Major companies operating in the urinary incontinence & pelvic organ prolapse devices and equipment market include Boston Scientific Corporation, Coloplast A/S, Ethicon US, Becton Dickinson and Company, Johnson & Johnson, Teleflex Incorporated, Medtronic plc, COVIDien, Cook Medical, Neomedic International, CooperSurgical, MedGyn, Personal Medical Corp, Integra LifeSciences, Panpac Medical, Medesign, Smiths Medical Inc., Thomas Medical, Kangge Medical, Dr. Arabin GmbH & Co. KG, American Medical Systems Inc., Caldera Medical Inc., Intuitive Surgical, InControl Medical LLC, Atlantic Therapeutics Ltd., Axonics Modulation Technologies, Convatec Group plc, Laborie, NUVO Group, Pelvalon, pfm medical, Promedon, Prosurg Inc., UROMED Kurt Drews KG, Verathon Inc., Vitality Medical, Women's Choice Pharmaceuticals, Zimmer Biomet Holdings Inc.

North America was the largest region in the urinary incontinence & pelvic organ prolapse devices and equipment market in 2023. Western Europe was the second-largest region in the urinary incontinence & pelvic organ prolapse devices and equipment market report. The regions covered in the urinary incontinence & pelvic organ prolapse devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the urinary incontinence & pelvic organ prolapse devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The urinary incontinence & pelvic organ prolapse devices and equipment market consist of sales of artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters that are used for the treatment of pelvic organ prolapse and urinary incontinence. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.